EP0287329B1 - Chromogenic cryptahemispherands useful in detecting electrolytes - Google Patents
Chromogenic cryptahemispherands useful in detecting electrolytes Download PDFInfo
- Publication number
- EP0287329B1 EP0287329B1 EP88303275A EP88303275A EP0287329B1 EP 0287329 B1 EP0287329 B1 EP 0287329B1 EP 88303275 A EP88303275 A EP 88303275A EP 88303275 A EP88303275 A EP 88303275A EP 0287329 B1 EP0287329 B1 EP 0287329B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- group
- formula
- ion
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003792 electrolyte Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 76
- 238000012360 testing method Methods 0.000 claims description 61
- 230000004044 response Effects 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 30
- 239000011159 matrix material Substances 0.000 claims description 18
- -1 2,4,6-trinitroanilino Chemical group 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000001118 alkylidene group Chemical group 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 3
- 238000006138 lithiation reaction Methods 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 4
- 238000010168 coupling process Methods 0.000 claims 4
- 238000005859 coupling reaction Methods 0.000 claims 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 230000026030 halogenation Effects 0.000 claims 2
- 238000005658 halogenation reaction Methods 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 230000002152 alkylating effect Effects 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 150000001500 aryl chlorides Chemical class 0.000 claims 1
- 238000006254 arylation reaction Methods 0.000 claims 1
- 230000000802 nitrating effect Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 description 58
- 239000000203 mixture Substances 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 43
- 239000000243 solution Substances 0.000 description 39
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 36
- 239000011591 potassium Substances 0.000 description 36
- 229910052700 potassium Inorganic materials 0.000 description 36
- 239000000523 sample Substances 0.000 description 29
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 25
- 239000011734 sodium Substances 0.000 description 25
- 229910052708 sodium Inorganic materials 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 22
- 230000000236 ionophoric effect Effects 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 239000002555 ionophore Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 230000009102 absorption Effects 0.000 description 18
- 238000010521 absorption reaction Methods 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 230000008859 change Effects 0.000 description 17
- 229910001415 sodium ion Inorganic materials 0.000 description 17
- 239000010410 layer Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 14
- 229910001868 water Inorganic materials 0.000 description 14
- 0 C*C(CC1=C)=CC=C1NC Chemical compound C*C(CC1=C)=CC=C1NC 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 238000010828 elution Methods 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229920001903 high density polyethylene Polymers 0.000 description 8
- 239000004700 high-density polyethylene Substances 0.000 description 8
- 229910001414 potassium ion Inorganic materials 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 239000001103 potassium chloride Substances 0.000 description 7
- 235000011164 potassium chloride Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 5
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 230000000536 complexating effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000123 paper Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- LXOFYPKXCSULTL-UHFFFAOYSA-N 2,4,7,9-tetramethyldec-5-yne-4,7-diol Chemical compound CC(C)CC(C)(O)C#CC(C)(O)CC(C)C LXOFYPKXCSULTL-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 3
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 3
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 3
- BNHGVULTSGNVIX-UHFFFAOYSA-N 1-(2-ethoxyethoxy)ethanol Chemical compound CCOCCOC(C)O BNHGVULTSGNVIX-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010067973 Valinomycin Proteins 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- WIRUZQNBHNAMAB-UHFFFAOYSA-N benzene;cyclohexane Chemical compound C1CCCCC1.C1=CC=CC=C1 WIRUZQNBHNAMAB-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- FCFNRCROJUBPLU-UHFFFAOYSA-N compound M126 Natural products CC(C)C1NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC1=O FCFNRCROJUBPLU-UHFFFAOYSA-N 0.000 description 2
- 229910052593 corundum Inorganic materials 0.000 description 2
- 150000003983 crown ethers Chemical class 0.000 description 2
- 239000002739 cryptand Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- LPXDNEQTGPFOPF-UHFFFAOYSA-N hydron;1h-imidazol-1-ium;phosphate Chemical compound C1=CNC=N1.OP(O)(O)=O LPXDNEQTGPFOPF-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- FCFNRCROJUBPLU-DNDCDFAISA-N valinomycin Chemical compound CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O FCFNRCROJUBPLU-DNDCDFAISA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229910001845 yogo sapphire Inorganic materials 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- HJRJRUMKQCMYDL-UHFFFAOYSA-N 1-chloro-2,4,6-trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(Cl)C([N+]([O-])=O)=C1 HJRJRUMKQCMYDL-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- JNNYORXBWHMVNV-UHFFFAOYSA-N CN=C(C=C1)C=CC2=C1O2 Chemical compound CN=C(C=C1)C=CC2=C1O2 JNNYORXBWHMVNV-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940095564 anhydrous calcium sulfate Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- FIMJSWFMQJGVAM-UHFFFAOYSA-N chloroform;hydrate Chemical compound O.ClC(Cl)Cl FIMJSWFMQJGVAM-UHFFFAOYSA-N 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- FDSGHYHRLSWSLQ-UHFFFAOYSA-N dichloromethane;propan-2-one Chemical compound ClCCl.CC(C)=O FDSGHYHRLSWSLQ-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002143 fast-atom bombardment mass spectrum Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005048 flame photometry Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- ZTZNHWQYDCBMKK-UHFFFAOYSA-N methylsulfanylmethane;oxolane Chemical compound CSC.C1CCOC1 ZTZNHWQYDCBMKK-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 238000007704 wet chemistry method Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
Definitions
- ionophore includes, broadly, molecules capable of forming a complex with an ion in solution.
- the cyclic polypeptide valinomycin
- binds selectively to potassium ions in solution to form a cationic complex are also included in the term.
- crown ethers, cryptands, podands, spherands, hemispherands and cryptahemispherands are also included in the term.
- lower alkylidene includes methylene, ethylidene, n-propylidene, isopropylidene, n-butylidene, sec-butylidene and tert-butylidene.
- Lower alkenyl means vinyl or lower alkyl substituted vinyl.
- the chromogenic cryptahemispherand of the present invention allows a significant degree of latitude as to its geometry and chemical nature, dependent upon selection of the variable parameters such as R, R', R'', Q, a, b, m and n, x and y. It is careful selection of these parameters that permits tailoring of the molecule to alter ion selectivity.
- variable parameters such as R, R', R'', Q, a, b, m and n, x and y. It is careful selection of these parameters that permits tailoring of the molecule to alter ion selectivity.
- molecules can be custom synthesized such that the internal cavity of the bicyclic structure can vary greatly as to its physical dimensions, and can be rendered more or less electron-rich.
- the chromogenic cryptahemispherands of the present invention can be made adaptable to the detection of cations.
- the bridgehead nitrogen atoms are uncharged, and their unshared electron pairs are available to participate with other electron-rich atoms in the molecule in rendering it an electron-rich environment conducive to receiving and complexing with a cation.
- the molecule can virtually "lock in" the entrapped ion, thereby dramatically increasing the association constant, K a , of the complex.
- Compound I includes as part of its structure a particular kind of chemically configured moiety, Q, which is capable of changing its physico-chemical characteristics when a complex is formed by an ion and compound (I). That is to say, if the target ion, i.e., the ion for which the structure of (I) has been tailored to selectively accept to form an ionophore/ion complex, is present in a test sample, whether or not other ions are present, a detectable change in those physico-chemical properties takes place.
- This capabaility of Q to exhibit such a response to complexation contributes greatly to the usefulness of (I) in assaying the analyte, or target, ion.
- compositions useful in such analyses can be formulated and used at a relatively mild pH, such as in the range of about 5-9, preferably between 6 and 8.
- a relatively mild pH such as in the range of about 5-9, preferably between 6 and 8.
- Yet another advantage of the preferred embodiment is that it is capable of functioning in an essentially aqueous environment, without the attendant need of a separate hydrophobic phase.
- compositions which, when prepared as an aqueous solution, are found useful for detecting the presence of certain ions, such as potassium, sodium, lithium, and others.
- Such compositions include, in addition to compound (I), a buffer to provide a pH environment of about 5 to about 9.
- the buffer provides a pH of about 6 to 8.
- the composition may contain manufacturing excipients, stabilizers, surfactants and other inert ingredients, all of which are easily within the ken of one skilled in the art, or which could be routinely determined at the bench without the need for undue experimentation.
- test sample In use the test sample is merely contacted with the composition and the detectable response is observed.
- the compound of Fig. 5 it has been found convenient to assess the response as light absorbed such as at 500 nanometers (nm).
- a relatively large volume of a solution of the compound of Fig. 5 at a pH of about 6-8 To a small amount of an aqueous test sample is added a relatively large volume of a solution of the compound of Fig. 5 at a pH of about 6-8. The mixture is put into a cuvette and observed spectrophotomerically at about 500 nm.
- Experiments using varied known potassium concentrations yield a dose-response curve enabling clear correlation between change in absorbance corresponding to various potassium concentrations in the millimolar range.
- the chromogenic compounds (I) can be used in a test device.
- a test device is obtained which facilitates ion assay yet further.
- Such a device lends itself to dry storage when not in use, thus enabling long shelf-life, and can be pressed into service immediately simply by contacting it with a small portion of the test sample, be it blood, serum, urine or other aqueous solution to be assayed. It can take on such formats as a dip-and-read strip for urine or a test slide for use with an automatic blood analyzer, or can from a multilayer structure such as is described in United States Patent Nos. 3,992,158 and 4,292,272.
- the dried, impregnated carrier matrix can then be mounted, if desired, on a suitable support such as a circumferential frame which leaves the matrix exposed in the middle; or the matrix can be mounted at one end of a plastic strip, the other end serving as a convenient handle.
- a suitable support such as a circumferential frame which leaves the matrix exposed in the middle; or the matrix can be mounted at one end of a plastic strip, the other end serving as a convenient handle.
- test device for the analysis of potassium for instance, can comprise the treatment of a porous high density polyethylene matrix with a surfactant to render it wettable, the impregnation of a reagent mixture containing the compound of Fig. 5, a binder and a buffer, and the drying of the reagent mixture on the porous matrix.
- test sample In use the test sample is contacted with the surface of the test device and the detectable response is measured at 580 nm or other wavelength on a reflectometer.
- detectable response is measured at 580 nm or other wavelength on a reflectometer.
- the present invention can be adapted for use in carrying out a myriad of ion assays, both manually and on automated systems, which assays are applicable to a broad field. Not only is clinical chemistry part of that field, but also chemical research, chemical process control, and quality assurance are a few of the many possible applications of this technology.
- the composition and test device are well suited for use in clinical testing of body fluids such as blood, blood serum and urine, since in this work a large number of repetitive tests are frequently conducted, and test results are often needed soon after the test sample is taken from the patient.
- test composition and device are used by contacting with the test sample, and observing a detectable response.
- a portion of test sample is placed on the test device for a sufficient period of time (such as several minutes). If desired, excess sample may be removed, such as by washing in a gentle stream of water with subsequent blotting with tissue paper, or washing in a gentle stream of water.
- Two sets of 6 test samples were prepared, one containing potassium chloride, the other sodium chloride.
- Stock buffer solutions were prepared at pH 5.0, 6.0, 7.0, 8.0, 9.0 and 10.0.
- To a 2.0 ml aliquot of each solution was added 0.1 mL of 0.1 M KCl to form the first set of samples.
- the procedure was repeated except 0.1 mL of 0.1 M NaCl was used instead of KCl to form the second set of samples.
- To each sample was then added 2 mL of 7 x 10 ⁇ 5 M of the compound of Fig. 5 in methylene chloride. Each sample was then thoroughly agitated on a Vortex mixer for 1-2 minutes.
- the samples were set aside briefly to allow phase separation, and the absorbance of the CH2Cl2 phase was then measured at 300-700 nm on a Beckman DU-8 spectrophotometer.
- a blank sample was run to provide a control.
- the blank was prepared as indicated above except that deionized water was used instead of KCl or NaCl solution.
- Aqueous 0.1 M buffer solutions were prepared, to yield solutions at a pH of 6.0, 6.6, 7.0, 8.0, and 9.0. To each of these was added an amount of the compound of Fig. 5 in dioxane to assure a final concentration of 0.1 mM of the compound of Fig. 5. The volume of dioxane was varied to achieve concentrations of 1%, 25% and 50% by volume of dioxane. Thus three sets of reagent solutions were prepared, all being 0.1 mM of the compound of Fig. 5. Each set comprised the 5 pH levels, but each set varied from one another in dioxane percentage.
- the treatment comprised depositing on one side of each disk a 30 uL aliquot of stock reagent solution, which permeated the entire disk, and allowing the disks to dry at room temperature for five hours with subsequent storage in a dessicator charged with anhydrous calcium sulfate for 2 hours.
- the disks were tested by innoculation with 25 uL of analytical specimens of 0.2 M MES buffer7 at pH 6, containing concentrations of 1.0 mM, 2.0 mM, 3.0 mM, 5.0 mM and 7.5 mM, respectively, in potassium. 7 2-(N-morpholino) ethane sulfonic acid
- a porous high density polyethylene substrate 35 um pore size and 1/32 inch thick was die cut into 1/2 inch diameter disks. These disks were rendered hydrophilic by treatment with 1% Surfynol 104 (Air Products and Chemicals, Wayne Pennsylvania) in chloroform and drying.
- a reagent solution was prepared by dissolving 18 mg of the compound of Fig. 6 as its lithium bromide complex, in 1.65 mL diethyleneglycol monoethyl ether. To this was added 48ml of 0.2M HEPES buffer pH 7.3 followed by 0.13 mL of TRITON X-100 and the mixture thoroughly stirred.
- RA-1000® system from Technicon Instruments was used to assay samples by discerning the change in absorbance of individual sample and reagent mixtures over a period of nine minutes and using the following instrument parameters: Sample volume 4.0 ⁇ l Reagent volume 395 ⁇ l Optical filter 500 nm Temperature 37°C Delay 15 sec. Incubation 9 min. Calibration Factor 1.0 Printer Format 3 Assay Type rate
- the spectrophotometric data obtained from this procedure with aqueous sodium chloride calibrants is linear over the clinically significant range of 80mM to 200mM sodium in human serum. Specific values for the calibration curve are: slope, 0.0023 ⁇ absorbance units per mM in sodium concentration, intercept -0.025; correlation coefficient, r, 0.9996.
- the spectrophotometric data obtained from this procedure showed a linear relationship between the change in absorbance of the reaction mixture and the logarithm of the sodium ion concentration in the sample over the clinically significant range of 80 mM to 200 mM, with a sensitivity of about 0.002 absorbance unit per mM change in sodium concentration.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Description
- The present invention relates to certain compounds, chromogenic cryptahemispherands, and their use for the measurement of ions, in particular ions in aqueous solution, and to a test means or device utilizing one or more of the compounds for performing such measurements.
- The invention provides a quick, facile way of assaying such ions whereby results are available to the assayist momentarily after merely contacting a test sample solution with the test means or device. There is no need for cumbersome, expensive electronic equipment such as ion-selective electrodes, flame photometers, atomic absorption spectrophotometers or the like, as previously used. Nor is it necessary to resort to known time-consuming wet chemistry techniques such as titration and other laboratory procedures. The present invention can enable the analyst to merely contact the test sample with a test composition or a dry test device, test slide, or similar test means or configuration, and observe any colour change or other detectable response. The present invention can also enable an unusually fast assay and unexpectedly high degree of selectivity, thereby permitting the detection of relatively low concentrations of an analyte ion even in solutions having relatively high concentrations of different, potentially interfering ions, while providing selectivity and accuracy to a degree heretofore unknown.
- The determination of aqueous ion concentration has application in numerous technologies. In the water purification art, calcium concentration must be carefully monitored to assess the degree of saturation of an ion exchange resin deionizer. Measurement of sodium and other ions in seawater is important in the preparation of drinking water aboard a ship at sea. Measurement of the potassium level in blood aids the physician in the diagnosis of conditions leading to muscle irritability and excitatory changes in myocardial function. Such conditions include oliguria, anuria, urinary obstruction and renal failure due to shock.
- Needless to say, a rapid, easy-to-perform method for determining the presence and concentration of a specific ion in aqueous samples would greatly enhance the state of these technologies, as well as any others where such quick, accurate determinations would be beneficial. Thus, for example, if a medical laboratory technician could accurately measure the potassium or sodium level of a serum, whole blood, plasma or urine sample in a matter of seconds or minutes, it would aid the physician in early diagnosis, and laboratory efficiency would increase manyfold. The present invention affords these and other unexpected advantages.
- Prior to the present invention, methods for determining ions in solution included flame photometry, atomic absorption photometry, ion-selective electrodes, multiple liquid phase partitioning and colorimetric slides. The use of certain compounds and compositions which selectively complex with, and therefore isolate, certain ions from the sample solution has become popular in ion-selective electrodes. These substances, known as ionophores, have the capability of selectively isolating ions from their counter ions and other ions in a test sample, thereby causing a charge separation and a corresponding change in electrical conductivity in the phase containing the ionophore. Illustrative of other uses of the ion/ionophore phenomenon include ion assays utilizing membrane electrodes, liquid/liquid partitioning, fluorescence, various reporter substances, and chromogenic derivatives of certain ionophoric compounds.
- Many technological developments have occurred since the early recognition that antibiotics such as valinomycin are capable of complexing certain ions and transporting them into the hydrophobic internal region of a cell membrane and, ultimately, into the cell nucleus. This basic ionophore discovery has led to the invention of a myriad of assay techniques for such ions as potassium, sodium, calcium and others; and has spawned a variety of diagnostic procedures of invaluable assistance to the chemist and physician. Moreover, countless new ionophore compounds have been discovered and invented of such chemical and structural diversity and complexity as to engender a whole new area of organic chemistry.
- Certain applications of these technologies to ion determination, however, have met with problems. Although ionophores can possess high ion selectivity, the presence of high concentrations of other ions relative to the ion of interest can lead to interference in the desired result. Thus, if an ionophore were to have a specificity ratio of 50:1 for complexing with ion X⁺ over ion Y⁺, nevertheless if Y⁺ were present in solution at a concentration 50 times that of X⁺, the resultant selectivity of the system for X⁺ would be diminished to such a great extent as to render the ionophore practically useless as an assay reagent for X⁺. Such disparity of concentrations occurs, for example, in blood where normal sodium/potassium concentration ratios are in the neighborhood of 35:1.
- Moreover, some prior art assays utilizing prior art ionophores have heretofore required a highly alkaline medium in order to function usefully, and aspects which contribute to poor shelf life as well as corrosiveness. Such systems also require a hydrophobic phase to contain or segregate the ionophore from the aqueous test sample, thus leading to organic/aqueous systems which respond relatively slowly.
- Thus, it would be desirable to greatly increase selectivity in a chromogenic ionophore, thereby overcoming interference from competing ions present at much higher concentrations. Likewise, it would be desirable to obviate the need for harshly alkaline conditions and a multiphasic system. These and other unexpected advantages have been realized through utilizing the unique compounds described herein.
- Briefly stated, the present invention resides in the discovery of a new class of compounds defined herein as "chromogenic cryptahemispherands", which have the structure (I):
wherein each R is independently hydrogen, or an unsubstituted or methyl-substituted alkyl or alkylidene group of up to 4 carbon atoms, or a vinyl group or a vinyl group substituted by an alkyl group of up to 4 carbon atoms, or an allyl or pyridyl, phenyl or benzyl group; each R' is independently an unsubstituted or methyl-substituted alkyl or alkylidene group of up to 4 carbon atoms, or a vinyl group or a vinyl group substituted by an alkyl group of up to 4 carbon atoms, or an allyl or pyridyl, phenyl or benzyl group; each R'' is independently hydrogen, or an unsubstituted or methyl-substituted alkyl or alkylidene group of up to 4 carbon atoms, or a vinyl group or a vinyl group substituted by an alkyl group of up to 4 carbon atoms, or an allyl or pyridyl, phenyl or benzyl group;
a,b,m and n are each independently from 1 to 3;
x is 1 to 4;
y is 1 to 4; and
Q is a chromogenic moiety of formula II
where R is as defined above and G is selected from
The invention also includes a composition for detecting the presence of an ion in solution, such as potassium and sodium, and a method for its use. The composition comprises the compound and a buffer capable of providing a pH in the range of about 5-9. Incorporation of the composition into a carrier matrix provides a dry test device for use in determining specific ions in solution. Both the composition and the device are utilized by contacting either with a test sample suspected of containing the ion of interest, and observing a detectable response. - The invention also includes a process for making the compounds of the present invention, which process is more fully described hereinafter. The compounds of the invention can be made by stepwise syntheses, as will be clear to those skilled in the art, using appropriate reactants at each stage. One particular synthetic route is described herein, by way of example only, with reference to Figure 1 of the drawings. The compounds of Figures 6 and 7 can be made in a manner similar to that described for the compound of Figure 5.
- In the accompanying drawings:
- FIG. 1. describes a reaction pathway for synthesizing a preferred chromogenic cryptahemispherand discussed in Section 6.3 herein and shown in Fig. 5.
- FIG. 2 portrays the linear dose/response curve obtained from the preferred embodiment of the invention described in Section 10.2 herein.
- FIG. 3 shows the comparative data between the method of the present invention and the standard ISE method for potassium assay in random serum samples as described in Section 10.3 herein.
- FIG. 4 provides a dose/response curve for various potassium levels utilizing the test device of the present invention described in Section 10.5 herein.
- FIG. 5 depicts the structure of a preferred embodiment of the present invention whereby the compound shown is selective for potassium ion assay.
- FIG. 6 depicts the structure of a preferred embodiment of the present invention whereby the compound shown is selective for sodium ion in a rate measurement.
- FIG. 7 depicts the structure of a preferred embodiment of the present invention whereby the compound shown is selective for sodium ion in an end point determination.
- Certain terms and terminology used herein have the following meanings:
- The term "ionophore" includes, broadly, molecules capable of forming a complex with an ion in solution. For example the cyclic polypeptide, valinomycin, binds selectively to potassium ions in solution to form a cationic complex. Also included in the term are crown ethers, cryptands, podands, spherands, hemispherands and cryptahemispherands.
- As used herein, "chromogenic" is intended as meaning that characteristic of a chemical system whereby a detectable response is generated in response to an external stimulus. Thus, for example, a cryptahemispherand is chromogenic where it is capable of exhibiting a detectable response upon complexing with an ion, which detectable response is not limited solely to change in color as defined below.
- By the term "detectable response" is meant a change in or appearance of a property in a system which is capable of being perceived, either by direct observation or instrumentally, and which is a function of the presence of a specific ion in an aqueous test sample. Some examples of detectable responses are the change in or appearance of color, fluorescence, phosphorescence, reflectance, chemiluminescence, or infrared spectrum which are referred to generally as chomogenic responses. Other examples of detectable responses may be the change in electrochemical properties, pH and nuclear magnetic resonance.
- The term "lower alkyl", as used in the present disclosure includes an alkyl moiety containing about 1-4 carbon atoms. Included in the meaning of lower alkyl are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl and tert-butyl. These may be unsubstituted, or they may be methyl-substituted. "Lower alkylidene" is used in the same context as "lower alkyl", but designates an alkylene or alkylidene group (i.e. a divalent alkyl) having 1-4 carbon atoms. Thus, lower alkylidene includes methylene, ethylidene, n-propylidene, isopropylidene, n-butylidene, sec-butylidene and tert-butylidene. "Lower alkenyl" means vinyl or lower alkyl substituted vinyl.
- The term "aryl" means pyridyl, phenyl or benzyl.
- The expression "electron withdrawing group" means NO₂, CF₃, CN, and COOR, which have a tendency to withdraw electrons from a neighbouring group. Reference may be made, for example, to Advanced Organic Chemistry, Reactions, Mechanisms, and Structure, Third Edition, by Jerry March (John Wiley & Sons),
chapter 1. - The chromogenic cryptahemispherand of the present invention, generically depicted as compound (I) in
Section 4, supra, allows a significant degree of latitude as to its geometry and chemical nature, dependent upon selection of the variable parameters such as R, R', R'', Q, a, b, m and n, x and y. It is careful selection of these parameters that permits tailoring of the molecule to alter ion selectivity. Thus by following the teachings herein, molecules can be custom synthesized such that the internal cavity of the bicyclic structure can vary greatly as to its physical dimensions, and can be rendered more or less electron-rich. - As a result, very high selectivity for one ionic species in the presence of one or more other ions can be achieved. For example, the Experimental section,
Section 10, infra, illustrates the measurement of potassium concentration in solutions which contain relatively high concentrations of sodium. Thus, it is not only the structure and chromogenicity of the present compound which render it unique, but also, and perhaps more importantly, its adaptability to being fashioned to suit the intended ion of interest, thereby achieving heretofore unattainable selectivity for one type of ion in solution in the presence of another, even when the concentration of the latter far outstrips the former. - Accordingly, each branch of the bicyclic system (I) is variable, both in physical dimension, degree of electron-richness or electron deficiency, and in the nature of substituent groups. For example, by varying the number of the groups CR₂OCR₂ in each of the chains in which it occurs, the electron density affecting the cavity can be designed to suit both the charge of the ion to be detected as well as its ionic radius and other physical dimensions.
- The chromogenic cryptahemispherands of the present invention can be made adaptable to the detection of cations. The bridgehead nitrogen atoms are uncharged, and their unshared electron pairs are available to participate with other electron-rich atoms in the molecule in rendering it an electron-rich environment conducive to receiving and complexing with a cation. Moreover, because of the unique steric configurational aspects of the cavity of the molecule, contributed in part by the aromatic chain of the bicyclic structure, the molecule can virtually "lock in" the entrapped ion, thereby dramatically increasing the association constant, Ka, of the complex. Other ions in the test sample which might be attracted by the election-rich cavity are either too large to penetrate it or too small to be held by the cavity geometry and structure, thus leading in both cases to a very low Ka for competing ions in comparison to that of the ion for which the bicyclic ionophore has been tailored.
- Compound I includes as part of its structure a particular kind of chemically configured moiety, Q, which is capable of changing its physico-chemical characteristics when a complex is formed by an ion and compound (I). That is to say, if the target ion, i.e., the ion for which the structure of (I) has been tailored to selectively accept to form an ionophore/ion complex, is present in a test sample, whether or not other ions are present, a detectable change in those physico-chemical properties takes place. This capabaility of Q to exhibit such a response to complexation contributes greatly to the usefulness of (I) in assaying the analyte, or target, ion.
- The chromogenic moiety Q has the formula II:
in which R is as defined supra and G is:
Especially preferred for use as group G are 2,4,6-trinitroanilino; 2,6-dinitro-4-trifluoromethylanilino; 2,4-dinitro-6-trifluromethylanilino; 4-nitroanilino; 4-nitrophenylazo; 4-nitrostyryl; and 4-benzo-quinonmonoimino. It has been found that compound (I) is especially useful when Q has the structure - Of the compounds embodied by the present disclosure, one which has been found especially selective in the determination of K⁺, such as in blood, serum, add urine, is the compound having the structure of Fig. 5 derived from compound (I) wherein:
Q is compound (III);
R is hydrogen;
R' is CH₃;
R'' is CH₃;
a and b are 1;
m and n are 1; and
x and y are 2.
The chromogenic cryptahemispherand of Fig. 5 has been found to exhibit unusually high selectivity for potassium ion, even in solutions having many times higher concentrations of other monovalent cations such as sodium. Moreover, compositions useful in such analyses can be formulated and used at a relatively mild pH, such as in the range of about 5-9, preferably between 6 and 8. Yet another advantage of the preferred embodiment is that it is capable of functioning in an essentially aqueous environment, without the attendant need of a separate hydrophobic phase. Thus, the latter disadvantageous requirements of prior art ionophoric test systems have been eliminated by the advent of the present invention. - The compounds of the invention can be formulated into compositions which, when prepared as an aqueous solution, are found useful for detecting the presence of certain ions, such as potassium, sodium, lithium, and others. Such compositions include, in addition to compound (I), a buffer to provide a pH environment of about 5 to about 9. Preferably the buffer provides a pH of about 6 to 8. In addition, the composition may contain manufacturing excipients, stabilizers, surfactants and other inert ingredients, all of which are easily within the ken of one skilled in the art, or which could be routinely determined at the bench without the need for undue experimentation.
- In use the test sample is merely contacted with the composition and the detectable response is observed. In the case of the compound of Fig. 5, it has been found convenient to assess the response as light absorbed such as at 500 nanometers (nm). To a small amount of an aqueous test sample is added a relatively large volume of a solution of the compound of Fig. 5 at a pH of about 6-8. The mixture is put into a cuvette and observed spectrophotomerically at about 500 nm. Experiments using varied known potassium concentrations yield a dose-response curve enabling clear correlation between change in absorbance corresponding to various potassium concentrations in the millimolar range.
- The chromogenic compounds (I) can be used in a test device. Thus, by incorporating a suitable carrier matrix with the composition, a test device is obtained which facilitates ion assay yet further.
- Such a device lends itself to dry storage when not in use, thus enabling long shelf-life, and can be pressed into service immediately simply by contacting it with a small portion of the test sample, be it blood, serum, urine or other aqueous solution to be assayed. It can take on such formats as a dip-and-read strip for urine or a test slide for use with an automatic blood analyzer, or can from a multilayer structure such as is described in United States Patent Nos. 3,992,158 and 4,292,272.
- It is desirable that the carrier matrix comprise a porous or wettable material. Thus, in a single layer format the carrier matrix can be formed from materials such as paper, cardboard, porous polymers, polymer fiber and natural felts, and other suitable materials. Especially preferred as carrier matrix materials are filter paper, and porous high density polyethylene. In a multilayer analytical element format, the buffer can be stored in an upper layer and the chromogenic cryptahemispherand in a lower layer in a superposed laminar fashion. The matrices for these layers can be formed from materials such as gelatin, water soluble or water swellable polymers, and other suitable materials. In addition to these two layers, a spreading layer, a reflecting layer and a support material can be incorporated to form an integral analytical element.
- The device is prepared by incorporating the carrier matrix with the test composition and, if desired, providing the dried matrix with a support.
- Thus the composition is applied to the matrix by innoculating the surface of the matrix or by dipping it into a solution of the composition. The thus-impregnated matrix can then be dried at room temperature or at elevated temperatures, provided the temperature is not so high as to deleteriously affect the composition.
- The dried, impregnated carrier matrix can then be mounted, if desired, on a suitable support such as a circumferential frame which leaves the matrix exposed in the middle; or the matrix can be mounted at one end of a plastic strip, the other end serving as a convenient handle.
- Another way of making the test device, for the analysis of potassium for instance, can comprise the treatment of a porous high density polyethylene matrix with a surfactant to render it wettable, the impregnation of a reagent mixture containing the compound of Fig. 5, a binder and a buffer, and the drying of the reagent mixture on the porous matrix.
- In use the test sample is contacted with the surface of the test device and the detectable response is measured at 580 nm or other wavelength on a reflectometer. Experiments using varied known potassium concentrations yield a dose/response curve enabling clear correlation between changes in percent reflectance and potassium concentration in the millimollar range.
- The present invention can be adapted for use in carrying out a myriad of ion assays, both manually and on automated systems, which assays are applicable to a broad field. Not only is clinical chemistry part of that field, but also chemical research, chemical process control, and quality assurance are a few of the many possible applications of this technology. The composition and test device are well suited for use in clinical testing of body fluids such as blood, blood serum and urine, since in this work a large number of repetitive tests are frequently conducted, and test results are often needed soon after the test sample is taken from the patient.
- The test composition and device are used by contacting with the test sample, and observing a detectable response. In a typical analytical procedure, a portion of test sample is placed on the test device for a sufficient period of time (such as several minutes). If desired, excess sample may be removed, such as by washing in a gentle stream of water with subsequent blotting with tissue paper, or washing in a gentle stream of water.
- If the ion under analysis is present in the test sample, the complex of ionophore and ion will form, and a detectable response will appear. Where the moiety Q on compound (I) forms or changes color in response to the complex, such response is observed, either with the naked eye or instrumentally. Where Q is a fluorophore such as fluoroscein, a fluorescence spectrophotometer can be utilized to measure the detectable response formed in the test device (here, the appearance of or change in fluorescence). Other techniques useful in observing a detectable response include reflectance spectrophotometry, absorption spectrophotometry and light transmission measurements.
- When the test sample is blood serum, transmission or reflectance techniques can be used to detect and quantify the presence of any reaction products, the formation of which serves as the detectable response. In this case radiant energy such as ultraviolet, visible or infrared radiation, is directed onto one surface of the test device and the output of that energy from the opposite surface is measured. Generally, electromagnetic radiation in the range of from about 200 to about 900 nm has been found useful for such measurements, although any radiation permeating the test means and which is capable of signifying the occurrence or extent of the response can be used.
- Various calibration techniques are applicable as a control for the analysis. For example, a sample of analyte standard solution can be applied to a separate test means as a comparison or to permit the use of differential measurements in the analysis.
- A series of experiments was performed to investigate various aspects of the present invention. A description of experimental procedures and results is provided here to assist in the understanding of the basic concepts as well as to fully and clearly describe preferred embodiments.
- An experiment was performed to synthesize a preferred embodiment of compound (I), supra. The chromogenic cryptahemispherand prepared in this experiment is referred to in Section 6.3 as the compound of Fig. 5. The reaction pathway is depicted in Fig. 1.
- Preparation of Compound 2 A suspension of 30 g (0.12 mol) of 1,¹ 34 g (0.2 mol) of benzyl bromide, and 30 g (0.22 mol) of anhydrous K₂CO₃ in 600 mL of acetone was refluxed for 48 hours (h), evaporated under reduced pressure, the residue was dissolved in CHCl₃ and H₂O (600 mL of each) and the layers were separated. The organic extract was dried, concentrated to 50 mL, and added to an Al₂O₃ column (400 g) made up in 1:1 cyclohexane-benzene.
Elution of the column with 3 L of 1:1 cyclohexane-benzene gave 32.6 g (80%) of 2 as a colorless oil. The ¹H NMR spectrum (200 MHz, CDCl₃) gave absorptions at δ 5.04 (s, OCH₂, 2H) and 6.86-7.66 (m, ArH, 8H).
¹ Prepared in accordance with Pearson, D. E.; Wysong, R. D.; Breder, C. V. J. Org. Chem. 1967, 32, 2358-2360. - Preparation of
Compound 3 To a solution of 13.3 g (38.9 mmol) of 2 in 350 mL of THF under Ar at -78°C was added 85 mL of 1.3 M sec-butyllithium (cyclohexane). After stirring 8 min, the lithiation solution was cannulated over 8 min into 150 g (1.4 mol) of trimethyl borate in 350 mL of THF at -78°C. The mixture was stirred 30 min at -78°C, warmed to 0°C over 1 h, diluted with 500 mL of 2 N hydrochloric acid, and stirred 1 h at 25°C. Ether (0.8 L) was added, the mixture was stirred 8 h at 25°C, and the layers were separated. The aqueous layer was extracted with fresh ether (2 x 200 mL). Evaporation of the ether extracts (no drying) at 25°/30 mm gave 7.8 g (91%) of 3 as a moist oil which was stored at 5°C and used without further purification. The ¹H NMR spectrum [200 MHz, (CD₃)₂CO] gave absorptions at δ 5.04 (s, ArCH₂, 2H) and 7.14-7.86 (m, ArH, 8H). - Preparation of Compound 5 To a solution of 120 g (0.33 mol) of 4 (iodination of commercially available p-cresol via literature preparation)² in 1 L THF at 0°C under Ar was added 35 g (0.73 mol) of NaH (50% in mineral oil). After the vigorous reaction subsided, the cooling bath was removed, 76 g (0.6 mol) of dimethyl sulfate was added, and the mixture refluxed 6 h. The mixture was cooled to 25°C and CH₃OH was cautiously added to decompose excess dimethyl sulfate. Ethyl ether and 10% aqueous NaCl were added (600 mL of each), the layers were separated, and the organic layer was dried, evaporated and the residue was dissolved in 100 mL of cyclohexane. The solution was passed through a column containing 1 kg Al₂O₃ made up in petroleum ether. Elution of the column with CH₂Cl₂-petroleum ether mixtures (2-10% CH₂Cl₂) gave 5 as a colorless oil (lit. mp 25°C)³ in 82% yield (102 g). The ¹H NMR spectrum (200 MHz, CDCl₃) gave absorptions at δ 2.24 (s, ArCH₃, 3H), 3.82 (s, OCH₃, 3H), and 7.57 (s, ArH, 2H).
² Burger, A., et al.; J. Am. Chem. Soc., 67, pp.1416-1419 (1945).
³ Wilkinson, J. H., J. Chem. Soc., 626-627 (1951). - Preparation of Compound 6 A solution of 100 g (0.27 mol) of 5 in 1 L of ether under Ar was cooled to -78°C. A 110 mL portion of 2.5 M BuLi was added over 5 min and the resulting mixture stirred 10 min at -78°C. Carbon dioxide gas was vigorously bubbled through the suspension for 20 min, and the cold bath was allowed to warm to 25°C over 10 h. The suspension was diluted with 600 mL of 1 N aqueous NaOH, and the layers were separated. The aqueous layer was acidified with 6 N HCl and the white solid collected and dried at 25°C under vacuum to give 50 g (64%) of
crude 6. The ¹H NMR spectrum [200 MHz, (CD₃)₂CO] gave absorptions at δ 2.33 (s, ArCH₃, 3H), 3.85 (s, OCH₃, 3H), 7.64 (d, ArH, 1H), and 7.86 (d, ArH, 1H). - Preparation of
Compound 7 To a solution of 50 g (0.17 mol) of 6 in 400 mL of ether at 10°C was added excess CH₂N₂ (in ether). After stirring 10 minutes at 25°C, the excess CH₂N₂ was decomposed with acetic acid and the ether evaporated. The residue was dissolved in 40 mL of CH₂Cl₂ and flash chromatographed on 300 g of silica gel made up in CH₂Cl₂. Elution of the column with CH₂Cl₂ gave 47 g (90%) of 7 as a colorless oil. The ¹H NMR spectrum (200 MHz, CDCl₃) gave absorptions at δ 2.30 (s, ArCH₃, 3H), 3.85 (s, OCH₃, 3H), 3.92 (s, OCH₃, 3H), 7.59 (d, ArH, 1H), and 7.78 (d, ArH, 1H). - Preparation of
Compound 8 To a mixture of 7.8 g (35 mmol) of 3 and 27 g (88 mmol) of 7 in 200 mL of benzene and 50 mL of ethanol under Ar was added 100 mL of 2 M aqueous Na₂CO₃. To this vigorously stirred two-phase mixture was added 1.2 g (1 mmol) of tetrakis (triphenylphosphine)palladium and the mixture was refluxed 48 h (Note: 100 mg of fresh catalyst was added after 24 h reflux).⁴ The layers were separated and the organic layer was dried, evaporated and dissolved in 40 mL of CH₂Cl₂. The mixture was separated by flash chromatography on silica gel (250 g) made up in CH₂Cl₂. Elution of the column with ether-CH₂Cl₂ mixtures (1 and 2% ether, 2 L of each) gave 12.8 g (67%) of 8 as a colorless foam. The ¹H NMR spectrum (200 MHz, CDCl₃) showed absorptions at δ 2.32 (s, ArCH₃, 6H), 3.57 (s, OCH₃, 6H) 3.93 (s, OCH₃, 6H), 4.33 (s, OCH₂, 2H); and 6.60-7.61 (m, ArH, 12H).
⁴ Modeled after Miyoura, N.; Yanagi, T.; Suzuki, A., Syn. Comm. 1981, 11(7), 513-519. - Preparation of Compound 9 A suspension of 2 g (2 mmol) of 10% palladium on carbon and 11.1 g (20.6 mmol) of 8 in 250 mL of ethyl acetate was hydrogenated (3 atm H₂) in a Parr shaker for 2 h. After filtration and evaporation of the ethyl acetate, the residue was dissolved in 30 mL of CH₂Cl₂ and purified by flash chromatograph on Si Gel (150g) made up in CH₂Cl₂. Elution of the column with 2% ether-98% CH₂Cl₂ gave 7.1 g (77%) of 9 as a colorless foam. The ¹H NMR spectrum (200 MHz, CDCl₃) showed absorptions at δ 2.38 (s, ArCH₃, 6H), 3.60 (s, OCH₃, 6H), 3.92 (s, OCH₃, 6H), and 6.97-7.63 (m, ArH, 7H).
- Preparation of
Compound 10 To a stirred solution of 7.1 g (15.8 mmol) of 9 in 500 mL of 1:1 CHCl₃-CH₃CO₂H was added 20 mL of 70% HNO₃ over 2 min. After stirring 15 min, the solution was diluted with H₂O (1.2 L) and CHCl₃ (200 mL) and the organic layer was extracted with H₂O (3 x 1.2 L), dried, concentrated to 25 mL and flash chromatographed on Si. Gel (200 g) made up in CH₂Cl₂. Elution of the column with CH₂Cl₂ (1 L) and 49:1 CH₂Cl₂-Et₂O (3 L) gave 7.1 g (91%) of 10 as a yellow foam. The ¹H NMR spectrum (200 MHz, CDCl₃) gave absorptions at 2.42 (s, ArCH₃, 6H), 3.65 (s, OCH₃, 6H), 3.94 (s, OCH₃, 6H), 7.36 (d, ArH, 2H), 7.72 (d, ArH, 2H), and 8.30 (s, ArH, 2H). - Preparation of Compound 11 A mixture of 7.1 g (14.3 mmol) of 20, 20 g (0.16 mol) of dimethyl sulfate and 22 g (0.16 mol) of K₂CO₃ in 500 mL of acetone under Ar was refluxed 24 h, evaporated and the residue dissolved in 1 L of 1:1 CHCl₃-H₂O. The organic layer was dried, concentrated to 25 mL and flash chromatographed on 200 g of Si Gel made up in CH₂Cl₂. Elution of the column with CH₂Cl₂ (1 L) and 49:1 CH₂Cl₂-ether (2 L) gave 6.8 g (93%) of 11 as a colorless foam. The ¹H NMR spectrum (200 MHz, CDCl₃) gave absorptions at δ 2.39 (s, ArCH₃, 6H), 3.30 (s, OCH₃, 3H), 3.60 (s, OCH₃, 6H), 3.94 (s, OCH₃, 6H), 7.34 (d, ArH, 2H), 7.68 (d, ArH, 2H), and 8.25 (s, ArH, 2H).
- Preparation of
Compound 12 To a solution of 8 g (15.7 mmol) of 11 in 325 mL of CH₃OH was added 100 mL of H₂O and then 12 g (0.29 mol) of LiOH.H₂O. After stirring 14 h at 25°C, the mixture was diluted with 400 mL of H₂O, extracted with CH₂Cl₂ (2 x 50 mL) and the aqueous layer acidified topH 1 with concentrated HCl. Extraction of the aqueous suspension with ether (3 x 300 mL) and drying for 16 h at 95°/0.01 mm gave 5.6 g (74%) of 12 as an amorphous yellow powder. The ¹H NMR spectrum [200 MHz, (CD₃)₂CO] gave absorptions at δ 2.42 (s, ArCH₃, 6H), 3.37 (s, OCH₃, 3H), 3.65 (s, OCH₃, 6H), 7.45 (d, ArH, 2H), 7.75 (d, ArH, 2H), and 8.25 (s, ArH, 2H). - Preparation of Compound 13 A suspension of 2.44 g (5 mmol) of 12 in 8 mL (110 mmol) of purified thionyl chloride was stirred 2 h at 25°C under Ar (12 dissolved after ∼ 30 min). Dry benzene (30 mL) was added and the solution evaporated at 40°C/30 mm to remove the excess thionyl chloride. This procedure was repeated three times. The crude product was dried at 25°C/0.01 mm to give 2.6 g (∼ 100%) of 13 as a yellow foam and was used without further purification. The ¹H NMR spectrum (200 MHz, CDCl₃) gave absorptions at δ 2.44 (s, ArCH₃, 6H), 3.33 (s, OCH₃, 3H), 3.66 (s, OCH₃, 6H), 7.44 (d, ArH, 2H), 8.00 (d, ArH, 2H), and 8.32 (s, ArH, 2H).
- Preparation of
Compound 15 Compound 13 (2.6 g, 5 mmol) was dissolved in 150 mL of anhydrous benzene and transferred in 50 mL portions to a 50 mL gas-tight syringe. Similarly, 1.3 g (5 mmol) of 14 (available from Merck Chemicals) together with 1.5 g (15 mmol) of triethylamine was dissolved in 150 mL of anhydrous benzene and transferred to a 50 mL gas-tight syringe. These solutions were added via a syringe pump to an oven-dried 2 liter Morton flask containing 1200 mL of anhydrous benzene over 2 h with vigorous mechanical stirring under Ar at 12°C. After stirring for 8 h at 12°C, the suspension was warmed to 25°, filtered to remove triethylamine hydrochloride and evaporated. The residue was dissolved in 40 mL of CH₂Cl₂. Elution of a silica gel column with acetone-dichloromethane mixtures (10-30% of acetone) gave 2.1 g (60%) of 15 as a white solid which darkens above 320°C and melts/decomposes at ∼ 345°C. The mass spectrum (70 eV) showed a molecular ion at m/e 707. The ¹H NMR spectrum (200 MHz, CDCl₃) showed absorptions at δ 2.37 (s, ArCH₃, 6H), 2.85 (s, OCH₃, 3H), 3.41 (s, OCH₃, 6H), 3.05-3.88 (m, NCH₂, OCH₂, 22H), 4.30 (d, NCH₂, 2H), 7.17-7.23 (m, ArH, 4H), and 8.35 (s, ArH, 2H). - Preparation of Compound 16 A suspension of 560 mg (0.79 mmol) of 25 and 1 g of 10% palladium on charcoal in 200 mL of dimethylformamide was hydrogenated (3 atm H₂) in a Parr shaker for 2 h. The catalyst was removed by filtration and the filtrate diluted with CHCl₃ (500 mL) and H₂O (1.2 L) and the layers were separated. The organic layer was extracted with fresh H₂O (3 x 1.2 L), dried (K₂CO₃) and evaporated to give 520 mg (97%) of 16 as a colorless foam. The ¹H NMR spectrum (200 MHz, CDCl₃) showed absorptions at δ 2.32 (s, ArCH₃, 6H), 2.66 (s, OCH₃, 3H), 3.41 (s, OCH₃, 6H), 3.06-3.96 (m, NCH₂, OCH₂, 22H), 4.28 (d, NCH₂, 2H), 6.80 (s, ArH, 2H), 7.08 (s, ArH, 2H), and 7.13 (s, ArH, 2H).
- Preparation of Compound 17 A solution of 490 mg (0.72 mmol) of 16 in 100 mL of THF was heated to reflux under Ar and 2.0 mL (20 mmol) of borane-methyl sulfide was added. The methyl sulfide-THF was slowly distilled from the mixture over 70 min. The remaining solution (30 mL) was cooled to 5°C, 5 N aqueous NaCl was cautiously added to decompose excess borane, and THF (30 mL) and 5 N aqueous NaCl (50 mL) were added. The mixture was stirred for 10 days at 25°C, the THF was evaporated and the residue was extracted with CH₂Cl₂ (2 x 50 mL). The organic extracts were filtered through phase separator paper, concentrated to 5 mL and diluted with 150 mL of CH₃OH. After adding 0.4 g (4.8 mmol) of NaHCO₃ and 0.2 g (0.81 mmol) of picryl chloride to the CH₃OH solution and stirring 25 min. at 25°C, the mixture was diluted with CH₂Cl₂ (40 mL) and 100 mL of 1 N aqueous NaCl. The layers were separated, and the organic layer (no drying) was added to a silica gel column (100 g) made up in 2% CH₃OH-98% CH₂Cl₂. Elution of the column with CH₃OH-CH₂Cl₂ mixtures (2-5% CH₃OH) gave 40 mg (6%) of the 17 KCl complex. The NMR spectrum (200 MHz, CDCl₃) showed absorptions at δ 2.36 (s, ArCH₃,6H), 2.84 (s, OCH₃,3H), 3.48 (s, OCH₃ 6H), 2.18-4.10 (m, NCH₂, 24H), 2.67 (d, ArCH₂N, 2H), 4.20 (d, ArCH₂N,2H), 7.03 (d, ArH, 2H), 7.12 (d, ArH, 2H), 7.17 (s, ArH, 2H) and 9.09 (s, ArH, 2H).
- Further elution of the column with CH₃OH-CH₂Cl₂ mixtures (10-20% CH₃OH) gave 250 mg (38%) of 17 NaCl complex as an orange foam. A Fab mass spectrum (m-nitrobenzyl alcohol dispersion) gave a base peak at m/e 883 (M + 23) corresponding to the M + Na ion and a lower intensity ion at 899(M + 39, 25% intensity of 883) corresponding to the M + K ion. The ¹H NMR spectrum of 17 NaCl (200 MHz, CD₂Cl₂) showed absorptions at δ 2.33 (s, ArCH₃, 6H), 2.12-4.00 (m, NCH₂, OCH₂, 24H), 2.95 (d, ArCH₂N, 2H), 4.06 (d, ArCH₂N, 2H), 4.06 (d, ArCH₂N, 2H), 7.02-7.13 (m, ArH, 6H) and 8.85 (s, ArH, 2H).
- An experiment was conducted to assess the performance of the present invention in the analysis of potassium ion in an aqueous system, in a presently preferred embodiment.
- Accordingly, a reagent solution of the invention was prepared by dissolving 15 mg of the compound of Fig. 5, as its sodium salt, in 1.65 mL diethylene glycol monoethyl ether. To this was added 48 mL of 0.1M HEPES buffer⁵ (pH = 7.3), followed by 0.17 mL of Brij-35⁶ solution (30% w/v) in distilled water, and the mixture thoroughly stirred.
⁵ HEPES buffer is prepared by adding 2.38 g of N-2-hydroxy-ethylpiperazine-N-2-ethane sulfonic acid to 90 mL distilled water, adding sufficient 1M tetramethylammonium hydroxide to bring the pH to 7.3, and adding distilled water to bring the volume to 100 mL.
⁶ Brij-35 is polyethoxylauryl ether - A spectrophotometric automated instrument known as the RA-1000® system available from Technicon Instruments Corporation was used to assay the samples. The following instrument parameters were used:
Sample volume 5.5 µl Reagent volume 385.0 µl Optical filter 500 nm Temperature 37°C Delay 5 min. Assay Type end point Calibration Factor 1.0
The spectrophotometric data obtained from this procedure is shown in Fig. 2, wherein potassium concentration is plotted against the change in light absorbance (△ Absorbance) at 500 nm. It can be seen that a linear dose-response curve, having a slope conducive to easy differentiation between absorbence levels, is obtained. - The preferred aqueous system of the present invention yielded a linear dose/response curve with a slope enabling easy point differentiation using photometric methods (△ absorption at 500 nm).
- An experiment was conducted to compare the present invention with an art-established procedure for measuring potassium in serum.
- A series of random serum samples containing a broad range of potassium concentration was obtained. These were analyzed on a RA-1000® system as in 10.2, supra, and also by the RA-1000® ISE mode. The instrument parameters were the same as those in Section 10.2 for the light absorbance mode.
- The comparative data is shown in Fig. 3, and shows excellent correlation between the method of the present invention and the standard ISE method for potassium concentrations in the range of 1-10 mM.
- An experiment was conducted to study the selectivity of a compound of the present invention for potassium ion in the presence of sodium ion, where the pH of the aqueous phase was varied within an extraction system containing an immiscible organic solvent.
- Two sets of 6 test samples were prepared, one containing potassium chloride, the other sodium chloride. Stock buffer solutions were prepared at pH 5.0, 6.0, 7.0, 8.0, 9.0 and 10.0. To a 2.0 ml aliquot of each solution was added 0.1 mL of 0.1 M KCl to form the first set of samples. The procedure was repeated except 0.1 mL of 0.1 M NaCl was used instead of KCl to form the second set of samples. To each sample was then added 2 mL of 7 x 10⁻⁵ M of the compound of Fig. 5 in methylene chloride. Each sample was then thoroughly agitated on a Vortex mixer for 1-2 minutes. The samples were set aside briefly to allow phase separation, and the absorbance of the CH₂Cl₂ phase was then measured at 300-700 nm on a Beckman DU-8 spectrophotometer. A blank sample was run to provide a control. The blank was prepared as indicated above except that deionized water was used instead of KCl or NaCl solution.
- The results are shown in Table 1 in terms of change in light absorbance from the control data at 450 nm (△ A). The data shows that significant response to both sodium and potassium occurred at pH levels in the range of 7.0 to 10.0, indicating poor discrimination between K⁺ and Na⁺, whereas at pH levels below 7.0, selectivity ratios of from 17.1 to 5.4 were obtained. This increase in ion selectivity with lowering pH was unexpected.
Table 1 Effect of pH on Sodium and Potassium Response Utilizing Extraction in CH₂Cl₂ (△ A at 450 nm) pH 5.0 6.0 7.0 8.0 9.0 10.0 Na⁺ 0.009 0.054 0.509 0.475 0.493 0.400 K⁺ 0.154 0.293 0.682 0.503 0.586 0.493 - An experiment was conducted to show the effects of (a) pH and (b) the concentration of a water-soluble organic solvent, on a preferred aqueous system of the present invention. Accordingly, solutions of KCl and NaCl were prepared in water at varying pH levels using standard buffers and with varying amounts of dioxane added.
- Aqueous 0.1 M buffer solutions were prepared, to yield solutions at a pH of 6.0, 6.6, 7.0, 8.0, and 9.0. To each of these was added an amount of the compound of Fig. 5 in dioxane to assure a final concentration of 0.1 mM of the compound of Fig. 5. The volume of dioxane was varied to achieve concentrations of 1%, 25% and 50% by volume of dioxane. Thus three sets of reagent solutions were prepared, all being 0.1 mM of the compound of Fig. 5. Each set comprised the 5 pH levels, but each set varied from one another in dioxane percentage.
- To 2.0 mL of each sample of reagent was added 0.1 mL of 1.0 M NaCl or KCl in water in an optical cuvette. Following mixing, light absorbance was measured on a Beckman DU-8 spectrophotometer at 300-700 nm. The data is shown in Table 2.
Table 2 Effect of pH and Dioxane on Sodium and Potassium Responses (△ A at 450 nm) to the Compound of Fig. 5 in Aqueous Medium Dioxane pH 6.0 6.6 7.0 8.0 9.0 1% Na⁺ 0.005 0.000 0.002 0.026 0.000 K⁺ 0.003 0.414 0.512 0.098 0.006 25% Na⁺ 0.002 0.001 0.000 0.016 0.086 K⁺ 0.014 0.035 0.018 0.352 0.175 50% Na⁺ 0.002 0.000 0.013 0.039 0.072 K⁺ 0.032 0.012 0.007 0.061 0.005 - In one set of data, that utilizing
pH 7 solutions (0.1 M HEPES buffer) with 1% dioxane, no response to sodium was detected, whereas a considerable response to potassium occurred. Accordingly, the present invention exhibits an enormously high selectivity ratio for potassium over sodium at neutral pH with negligible organic solvent present (See Fig. 3). Such unexpected selectivity in chromogenic ionophores is heretofore unreported. - The overall data in Table 2 shows that as the organic solvent portion of the reagent was increased, both selectivity and sensitivity for potassium over sodium decreased. This phenomenon is contrary to results described in previously published works, where other ionophores, particularly crown ethers and cryptands, exhibited increased sensitivity and selectivity with increasing porportions of organic reagents. The present invention exhibits the reverse phenomenon.
- Moreover, sensitivity and specificity appears inversely proportional to pH, whereas the above-mentioned previous results with other ionophores generally exhibited the opposite tendency.
- An experiment was performed to prepare a test device of the present invention capable of detecting the presence of potassium, whereby a carrier matrix of high density polyethylene (HDPE) was incorporated with the compound of Fig. 5.
- Porous disks having 1/2 inch diameters, a thickness of 1/32 inch, and a 35 um pore size were obtained from Porex Technologies, Inc., Fairburn, GA. These were pretreated by saturating with a 1% w/v solution of Surfynol 104 nonionic detergent (Air Products, Inc.) in chloroform and drying. The disks were then each treated with 30 uL of reagent solution. The stock reagent solution comprised a mixture of 0.9 mL distilled water, 0.1 mL diethylenglycolmonoethyl ether, 5 mg of the compound of Fig. 5 and 40 mg polyvinylpyrrolidone. The treatment comprised depositing on one side of each disk a 30 uL aliquot of stock reagent solution, which permeated the entire disk, and allowing the disks to dry at room temperature for five hours with subsequent storage in a dessicator charged with anhydrous calcium sulfate for 2 hours.
- The disks were tested by innoculation with 25 uL of analytical specimens of 0.2 M MES buffer⁷ at
pH 6, containing concentrations of 1.0 mM, 2.0 mM, 3.0 mM, 5.0 mM and 7.5 mM, respectively, in potassium.
⁷ 2-(N-morpholino) ethane sulfonic acid - Following 2 minutes incubation with analytical specimen, the disks were observed at 580 nm for reflectance data using an Infra-Alyzer® (Technicon Instruments Corporation) modified for use in the visible portion of the electromagnetic spectrum.
-
- A porous high density polyethylene substrate, 35 um pore size and 1/32 inch thick was die cut into 1/2 inch diameter disks. These disks were rendered hydrophilic by treatment with 1% Surfynol 104 (Air Products and Chemicals, Wayne Pennsylvania) in chloroform and drying. A thirty microliter reagent aliquot containing 0.4M imidazole-phosphoric acid buffer at pH 5.8, 6% polyvinylpyrrolidone. (MW 40,000), 0.02% Brij-35 (ICI Americas Inc., Wilmington, Delaware), 10% 2-ethoxyethoxy ethanol, and 9 millimolar compound of Fig. 5 was deposited to each porous high density polyethylene disk. These reagent impregnated disks were allowed to dry at ambient conditions for four hours before being used for potassium measurement.
- To test the response of these dry test devices to various concentrations of potassium ions in serum samples, thirty microliters serum test sample was applied to each disk and incubated at room temperature for five minutes. The color changes were recorded on a reflectometer at 580 nm. The change in percent reflectance (%R) is indicative of a colorimetric response. The result is summarized in Table 3.
- To evaluate the accuracy of the determination of potassium ion in human serum samples, the same samples obtained from a hospital were analyzed for potassium using a flame photometer and compared with the potassium values obtained using the dry test device method. Correlation data between the two methods are as follows: slope, 0.995; intercept, 0.063; correlation coefficient, r, 0.991.
Table 3 Response of the compound of Fig. 5 to potassium ions in serum on "dry" test devices. [K⁺] mM Response (%R) 2 26.5 4 21.7 6 18.6 8 17.5 10 16.5 - An experiment was conducted to assess the performance of one example of the present invention in the analysis of sodium ion in an essentially aqueous reaction system.
- Accordingly, a reagent solution was prepared by dissolving 18 mg of the compound of Fig. 6 as its lithium bromide complex, in 1.65 mL diethyleneglycol monoethyl ether. To this was added 48ml of 0.2M HEPES buffer pH 7.3 followed by 0.13 mL of TRITON X-100 and the mixture thoroughly stirred.
- The RA-1000® system from Technicon Instruments was used to assay samples by discerning the change in absorbance of individual sample and reagent mixtures over a period of nine minutes and using the following instrument parameters:
Sample volume 4.0 µl Reagent volume 395 µl Optical filter 500 nm Temperature 37° C Delay 15 sec. Incubation 9 min. Calibration Factor 1.0 Printer Format 3 Assay Type rate - The spectrophotometric data obtained from this procedure with aqueous sodium chloride calibrants is linear over the clinically significant range of 80mM to 200mM sodium in human serum. Specific values for the calibration curve are: slope, 0.0023 △ absorbance units per mM in sodium concentration, intercept -0.025; correlation coefficient, r, 0.9996.
- To evaluate the accuracy of the determination of sodium ion in human serum, samples obtained from a hospital were analyzed for sodium using the RA-1000® Ion Selective Electrode and compared with the sodium values obtained using the spectrophometric method. Correlation data between the two methods are as follows: slope, 1.059; intercept, -8.82; correlation coefficient, r, 0.9852.
- The performance of another example of the present invention was assessed for the assay of sodium in serum samples using an essentially aqueous reaction system. Accordingly, 33 mg of the compound of Fig. 7 as its lithium bromide complex, were dissolved in 1.65 mL of diethyleneglycol monoethyl ether. To this was added 48 ml of 0.2M HEPES buffer pH 8.1 followed by 0.085 mL of Brij .35 30% (w/v) and the mixture thoroughly stirred.
- The RA-1000® System from Technicon Instruments was used to assay samples by discerning the change in absorbance of the reaction mixture after sample is added. The following parameters were used on the instrument:
Sample volume 2 µL Reagent volume 400 µL Optical filter 550 nm Temperature 37° C Delay 9 mins. Calibration factor 1.0 Printed format 3 Assay Type end point - The spectrophotometric data obtained from this procedure showed a linear relationship between the change in absorbance of the reaction mixture and the logarithm of the sodium ion concentration in the sample over the clinically significant range of 80 mM to 200 mM, with a sensitivity of about 0.002 absorbance unit per mM change in sodium concentration.
- Comparison of serum samples assayed by this spectrophotometric method and by the RA-1000® Ion Selective Electrode method were also made. Correlation data between the two methods are as follows: slope, 0.963; intercept, 6.22; correlation coefficient, r, 0.9946.
- A porous high density polyethylene substrate, 35 un pore size and 1/32 inch thick was die cut into 1/2 inch diameter disks. These disks were rendered hydrophilic by treatment with 1% W/V surfynol 104 (Air Products and Chemicals, Wayne, Pennslyvania) in chloroform and drying. A thirty microliters reagent aliquot containing 0.2M imidazole-phosphoric acid buffer pH 7.5, 0.2% W/V Triton X-100 (Rohn and Haas Co., Philadelphia, Pennsylvania), 10% W/V 2-ethoxyethoxyethanol, 7% W/V polyvinylpyrrolidone (MW 40,000), and 3 millimolar compound of Fig. 6 was deposited to each porous high density polyethylene disk. These reagent impregnated disks were allowed to dry at ambient conditions for four hours before being used for sodium measurement.
- To test the response of these dry test devices to various concentrations of sodium ions in aqueous medium, thirty microliters aqueous test solution was applied to each disk and incubated at 37°C for six minutes. The color changes were recoreded on a reflectometer at 560 nm. The change in percent reflectance (%R) is indicative of a colorimetric response. The result is summarized in Table 4. The data clearly show that the compound of Fig. 6 can be used to detect sodium ions in a dry test device.
Table 4 Response of the compound of Fig. 6 to sodium ions in aqueous medium on dry test devices. [Na⁺] mM Response (%R) K/S 0 21.4 1.443 2 18.2 1.838 4 17.6 1.929 6 16.9 2.043 8 16.5 2.113 10 15.2 2.365 15 14.0 2.641
Claims (10)
- A method of detecting the presence of an ion in aqueous test sample, the method comprising contacting the sample with a chromogenic cryptahemispherand and a buffer to provide a pH in the range 5 to 9, and observing a detectable response; wherein the chromogenic cryptahemispherand has the structure (I):
a,b,m and n are each independently from 1 to 3;
x is 1 to 4;
y is 1 to 4; and
Q is a chromogenic moiety of formula II - A method according to claim 1, wherein in formula II, R is R' and G is 2,4,6-trinitroanilino; 2,6-dinitro-4-trifluoro-methylanilino; 2,4-dinitro-6-trifluoromethylanilino; 4-nitroanilino; or 2,4-dinitrophenylazo.
- A method according to claim 1, wherein
G is 4-nitrophenylazo; 4-nitrostyryl; or 4-benzoquinomonoimino. - A method according to claim 1, 2 or 3, wherein the cryptahemispherand and the buffer are supported on a carrier matrix.
- A method of preparing a chromogenic cryptahemispherand (XX) having the structure
said method comprising the steps of:(a) coupling a compound (II) having the formula(d) coupling compound (VI) with a compound (VII) having the formula(g) coupling compound (X) with an activated aryl chloride to form compound (XX). - A method according to claim 5, in which compound (II) is prepared in a synthesis sequence comprising(a) halogenation of phenol to form 2,6-dihalophenol;(c) subjecting the ether to a lithiation/boronation reaction to obtain compound (II).
- A method according to claim 5 or 6, in which compound (III) is prepared in a synthesis sequence comprising(c) substituting one of the halogens of compound (B) with -CO₂R to form compound (III).
- A method according to claim 5,6 or 7 in which the coupling of compounds (II) and (III) is conducted in the presence of tetrakis(triphenylphosphine) palladium to form compound (IV).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38681 | 1987-04-15 | ||
US07/038,681 US4859606A (en) | 1987-04-15 | 1987-04-15 | Method for detecting cations in a test sample utilizing chromogenic cryptahemispherands |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0287329A2 EP0287329A2 (en) | 1988-10-19 |
EP0287329A3 EP0287329A3 (en) | 1989-12-06 |
EP0287329B1 true EP0287329B1 (en) | 1993-12-08 |
Family
ID=21901301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP88303275A Expired - Lifetime EP0287329B1 (en) | 1987-04-15 | 1988-04-12 | Chromogenic cryptahemispherands useful in detecting electrolytes |
Country Status (9)
Country | Link |
---|---|
US (1) | US4859606A (en) |
EP (1) | EP0287329B1 (en) |
JP (1) | JP2606721B2 (en) |
AU (1) | AU623587B2 (en) |
CA (1) | CA1290750C (en) |
DE (1) | DE3886084T2 (en) |
DK (1) | DK204088A (en) |
ES (1) | ES2060649T3 (en) |
IL (1) | IL84421A (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL84422A (en) * | 1987-04-15 | 1993-03-15 | Technicon Instr | Process for the preparation of chromogenic cryptahemispherands |
US5096831A (en) * | 1987-04-15 | 1992-03-17 | Miles Inc. | Reagents for determining cations |
US5073501A (en) * | 1987-04-15 | 1991-12-17 | Technicon Instruments Corporation | Method for determining the concentration of cations in a sample |
US5011924A (en) * | 1987-04-15 | 1991-04-30 | Technicon Instruments Corporation | Chromogenic cryptahemispherands and their preparation |
US5177221A (en) * | 1987-04-15 | 1993-01-05 | Miles Inc. | Chromogenic hemispherands and their preparation |
US5045475A (en) * | 1987-04-15 | 1991-09-03 | Technicon Instruments Corporation | Reagent for determining cations |
US5145787A (en) * | 1987-04-15 | 1992-09-08 | Miles, Inc. | Method for determining the concentration of cations in a sample |
US5162508A (en) * | 1987-12-18 | 1992-11-10 | Compagnie Oris Industrie | Rare earth cryptates, processes for their preparation, synthesis intermediates and application as fluorescent tracers |
US5064955A (en) * | 1990-06-04 | 1991-11-12 | Technicon Instruments Corporation | Large scale, non-chromatographic purification of chromogenic cryptahemispherands (1.1) and (2.1) |
EP0475045B1 (en) * | 1990-08-06 | 1996-12-11 | Bayer Corporation | Method and device for the assay of ions |
US5188802A (en) * | 1991-05-28 | 1993-02-23 | Eastman Kodak Company | Dry analytical element for lithium assay |
US5413732A (en) * | 1991-08-19 | 1995-05-09 | Abaxis, Inc. | Reagent compositions for analytical testing |
US5776563A (en) | 1991-08-19 | 1998-07-07 | Abaxis, Inc. | Dried chemical compositions |
US5262330A (en) * | 1992-02-27 | 1993-11-16 | Miles Inc. | Colorimetric methods and reagents for the assay of calcium in a test sample |
AT401823B (en) * | 1993-09-30 | 1996-12-27 | Avl Verbrennungskraft Messtech | OPTICAL INDICATOR FOR DETERMINING THE ACTIVITY OF AN ION IN A SAMPLE |
US5958782A (en) * | 1993-10-21 | 1999-09-28 | Minnesota Mining And Manufacturing Company | Cation-sensing composite structure and compounds for use therein |
US5474743A (en) * | 1993-10-21 | 1995-12-12 | Minnesota Mining And Manufacturing Company | Cation-sensing composite structure and compounds for use therein |
CA2256747A1 (en) | 1996-07-12 | 1998-01-22 | Minnesota Mining And Manufacturing Company | Method for the colorimetric quantification of ions |
AUPQ776800A0 (en) * | 2000-05-26 | 2000-06-22 | Seba Diagnostics Pty. Ltd. | Detection method and reagents |
US6962992B2 (en) | 2000-12-20 | 2005-11-08 | Molecullar Probes, Inc. | Crown ether derivatives |
US7579463B2 (en) * | 2000-12-20 | 2009-08-25 | Life Technologies Corporation | Crown ether derivatives |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4436923A (en) * | 1982-06-07 | 1984-03-13 | The President And Trustees Of The Miami University | Trifluoromethyl-substituted chromogenic crown ethers and methods of using same |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3847949A (en) * | 1970-05-12 | 1974-11-12 | Du Pont | Macrocyclic hetero imine complexing agents |
FR2155926B1 (en) * | 1971-10-15 | 1973-11-30 | Cetrane Laboratoire | |
US3966766A (en) * | 1973-03-26 | 1976-06-29 | Schering Corporation | Monocyclic macrocyclic compounds and complexes thereof |
US4156683A (en) * | 1973-03-26 | 1979-05-29 | Schering Corporation | Complexes of macrocyclic compounds |
US3965116A (en) * | 1974-09-12 | 1976-06-22 | The Regents Of The University Of California | Multioxymacrocycles |
DE2853064C2 (en) * | 1978-12-08 | 1987-05-14 | Henkel KGaA, 4000 Düsseldorf | Process for the preparation of oxalkylation products |
DE3202779A1 (en) * | 1982-01-28 | 1983-08-04 | Merck Patent Gmbh, 6100 Darmstadt | POTASSIUM REAGENT AND METHOD FOR DETERMINING POTASSIUM IONS |
SU1139730A1 (en) * | 1983-10-12 | 1985-02-15 | Ордена Ленина Институт Геохимии И Аналитической Химии Им.В.И.Вернадского | 1 ,12 -tetrasulfo-1 ,12 -tetraoxy-2,3,10,11,13,14,21,22-octaaza-5,8,16,19-tetraoxa-1,12 di(22,7) naphtha-4,9,15,20-tetra(1,2)phena-cyclodocoza-2,10,13,21-tetraen as reagent for photometric determination of berrilium |
GB8528804D0 (en) * | 1985-11-22 | 1985-12-24 | Amersham Int Plc | Compounds |
IL84422A (en) * | 1987-04-15 | 1993-03-15 | Technicon Instr | Process for the preparation of chromogenic cryptahemispherands |
US4808539A (en) * | 1987-04-15 | 1989-02-28 | Technicon Instruments Corporation | Compounds, reagents and procedures for determining cations |
-
1987
- 1987-04-15 US US07/038,681 patent/US4859606A/en not_active Expired - Lifetime
- 1987-11-10 IL IL84421A patent/IL84421A/en not_active IP Right Cessation
-
1988
- 1988-03-08 CA CA000560875A patent/CA1290750C/en not_active Expired
- 1988-03-11 AU AU13065/88A patent/AU623587B2/en not_active Ceased
- 1988-04-01 JP JP63078277A patent/JP2606721B2/en not_active Expired - Fee Related
- 1988-04-12 DE DE3886084T patent/DE3886084T2/en not_active Expired - Fee Related
- 1988-04-12 ES ES88303275T patent/ES2060649T3/en not_active Expired - Lifetime
- 1988-04-12 EP EP88303275A patent/EP0287329B1/en not_active Expired - Lifetime
- 1988-04-14 DK DK204088A patent/DK204088A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4436923A (en) * | 1982-06-07 | 1984-03-13 | The President And Trustees Of The Miami University | Trifluoromethyl-substituted chromogenic crown ethers and methods of using same |
Also Published As
Publication number | Publication date |
---|---|
AU1306588A (en) | 1988-12-08 |
JP2606721B2 (en) | 1997-05-07 |
EP0287329A3 (en) | 1989-12-06 |
JPS646861A (en) | 1989-01-11 |
US4859606A (en) | 1989-08-22 |
DE3886084T2 (en) | 1994-06-16 |
AU623587B2 (en) | 1992-05-21 |
DK204088A (en) | 1989-01-26 |
DE3886084D1 (en) | 1994-01-20 |
IL84421A (en) | 1993-01-14 |
ES2060649T3 (en) | 1994-12-01 |
IL84421A0 (en) | 1988-04-29 |
CA1290750C (en) | 1991-10-15 |
DK204088D0 (en) | 1988-04-14 |
EP0287329A2 (en) | 1988-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0287329B1 (en) | Chromogenic cryptahemispherands useful in detecting electrolytes | |
EP0125555B1 (en) | Unified test means for ion determination | |
EP0287327B1 (en) | Compounds for determining cations | |
US4670218A (en) | Ion test means having a porous carrier matrix | |
JPH04250360A (en) | Method and apparatus for ion assay | |
US4994395A (en) | Chromogenic cryptand reagents and methods for determining cation concentrations in test samples containing interfering cations | |
US4992381A (en) | Method of detecting electrolytes in an aqueous test sample using chromogenic hemispherands and test device therefor | |
US4734375A (en) | Ion specific test method | |
EP0125554B1 (en) | Ion test means having a hydrophilic carrier matrix | |
FI79696B (en) | NY INDONAFTOL-FOERENING ANVAENDBAR VID DETEKTERING AV IONER OCH FOERFARANDE FOER DESS FRAMSTAELLNING. | |
FI80150B (en) | IONTESTHJAELPMEDEL MED POROES BAERMATRIS. | |
US5177221A (en) | Chromogenic hemispherands and their preparation | |
AU650804B2 (en) | Colorimetric methods and reagents for the assay of calcium in a test sample | |
US5096831A (en) | Reagents for determining cations | |
US5011924A (en) | Chromogenic cryptahemispherands and their preparation | |
US5045475A (en) | Reagent for determining cations | |
US5073501A (en) | Method for determining the concentration of cations in a sample | |
US5145787A (en) | Method for determining the concentration of cations in a sample |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): BE CH DE ES FR GB IT LI NL SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Owner name: TECHNICON INSTRUMENTS CORPORATION(A DELAWARE CORPO |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): BE CH DE ES FR GB IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 19900109 |
|
17Q | First examination report despatched |
Effective date: 19911212 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Owner name: MILES INC.(AN INDIANA CORP.) |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE ES FR GB IT LI NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19931208 Ref country code: NL Effective date: 19931208 Ref country code: LI Effective date: 19931208 Ref country code: CH Effective date: 19931208 Ref country code: BE Effective date: 19931208 |
|
ITF | It: translation for a ep patent filed | ||
REF | Corresponds to: |
Ref document number: 3886084 Country of ref document: DE Date of ref document: 19940120 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2060649 Country of ref document: ES Kind code of ref document: T3 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 19950407 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19960413 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 19990301 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20040407 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20040420 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20040601 Year of fee payment: 17 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050412 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050412 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20051101 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20050412 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20051230 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20051230 |